Kadmon Holdings Inc

Kadmon — Investor Presentation (September 2017)

26 slides from Kadmon's investor presentation, Sep 25, 2017

  1. Slide 1: Corporate Presentation

    Corporate PresentationSeptember 15, 2017Kadmon Holdings, Inc.

  2. Slide 2: Forward-looking Statement

    Forward-looking StatementThis presentation contains "forward[] looking" statements that are based on the°beliefs and assumptions and on information currently available to management of°Kadmon Holdings, Inc. (the "Company").[] All statements other than statements°of historical fact contained in this

  3. Slide 3: Company Focus: Research-Focused Biopharmaceutical Company

    Company Focus Research-Focused Biopharmaceutical°Company Development-stage biopharmaceutical company headquartered in New York-- Approximately 100 employeesNear-term clinical focus on autoimmune and fibrotic diseasesResearch focus on autoimmune and fibrotic diseases as well as biologics in°oncology

  4. Slide 4: ROCK Inhibitor Platform: Autoimmune and Fibrotic Diseases

    ROCK Inhibitor PlatformAutoimmune and Fibrotic Diseases

  5. Slide 5: ROCK Signaling: Key Therapeutic Target

    ROCK Signaling: Key Therapeutic TargetROCK Signaling Plays a Key Role in Many Cell Functions[] ROCK (Rho associated coiled-coil containing protein kinase) is an "on"°switch in cells-- Two ROCK isoforms: ROCK1 and ROCK2[] ROCK signaling regulates cell movement, shape and differentiation[] Dysregulati

  6. Slide 6: Kadmon ROCK Inhibitor Platform

    Kadmon ROCK Inhibitor Platform[] Kadmon has developed a comprehensive portfolio of oral small molecule ROCK°inhibitors [] Includes a distinct series of ROCK2 and pan-ROCK (ROCK1/ROCK2)°inhibitors in preclinical and clinical development:-- ROCK2 inhibitors for autoimmune diseases -- Pan-ROCK inhibito

  7. Slide 7: Lead ROCK Compound: KD025

    Lead ROCK Compound: KD025 KD025 is Kadmon's Lead ROCK Inhibitor In Phase°2 Development [] Lead compound, KD025, is a ROCK2 inhibitor in Phase 2 clinical°development-- Demonstrated safety and efficacy in 8 completed clinical trials at doses up°to 1,000 mg QD -- Over 300 subjects dosed with KD025[] KD

  8. Slide 8: ROCK2 Rebalances Immune Response to Treat Immune Dysfunction

    ROCK2 Rebalances Immune Response to Treat Immune Dysfunction[] ROCK2 inhibition down-regulates pro-inflammatory Th17 responses and°increases Treg function, helping to resolve immune dysregulation-- Reduces STAT3 phosphorylation and increases STAT5 phosphorylation[] ROCK2 inhibition rebalances immune

  9. Slide 9: ROCK Signaling Mediates Multiple Fibrotic Processes

    ROCK Signaling Mediates Multiple Fibrotic Processes ROCK Signaling is a Key Therapeutic°Target for Fibrosis Fibrosis is a consequence of aberrant wound-healingCaused by unregulated myofibroblast proliferation, leading to uncontrolled°collagen and antibody Results in permanent scarring, potentially l

  10. Slide 10: ROCK Signaling Mediates Multiple Fibrotic Processes

    ROCK Signaling Mediates Multiple Fibrotic ProcessesROCK inhibition may reduce collagen deposition and fibroblast activation,°improving organ function 10

  11. Slide 11: KD025 Shifts the Th17 and Treg Balance in vitro

    KD025 Shifts the Th17 and Treg Balance in vitro KD025 Reduces Key Pro-Inflammatory Cytokines (IL-17) and Increases Regulatory T°Cells (Tregs) 11

  12. Slide 12: KD025 Pharmacokinetics (PK)

    KD025 Pharmacokinetics (PK)[] KD025 has high oral bioavailability [] KD025 half-life: 6-8 hours[] Linear PK within therapeutic exposure range [] Demonstrated clinical°activity as low as 200 mg QD-- (Achieving median C)max ~2,100 ng/mL (~5 []M) (and AUC)0-24 ~10,000 h.°ng/mL-- Little to no accumulati

  13. Slide 13: KD025 in Chronic Graft-Versus-Host-Disease (cGVHD)

    KD025 in Chronic Graft-Versus-Host-Disease (cGVHD)¨¨¨¨¨¨¨cGVHD: Complication Following Allogeneic Hematopoietic Stem Cell°Transplantation (HSCT) [] Common and often fatal complication following°allogeneic HSCT-- About 10,000 people receive allogeneic stem cell transplants in the United°States each y

  14. Slide 14: Ongoing Phase 2 Trial of KD025 in cGVHD

    Ongoing Phase 2 Trial of KD025 in cGVHDOpen-label, Dose-finding Trial of KD025 in cGVHD[] Open-label, dose-finding trial to evaluate the safety, tolerability and°activity of KD025 in adults with steroid-dependent or steroid-refractory cGVHD°and active disease [] 24-week study, with option to continu

  15. Slide 15: Preliminary Data Summary: Cohort 1 (KD025 200 mg QD)

    Preliminary Data Summary: Cohort 1 (KD025 200 mg QD)Preliminary Activity and Safety Summary[] Overall response rate ("ORR"), which includes partial and complete°responders at any time point, is 12 of 17 (71%) patients-- Of responders remaining on KD025 through week 24, 8 of 9 (89%) sustained°respons

  16. Slide 16: Preliminary Data Summary: Cohort 2 (200 mg BID)

    Preliminary Data Summary: Cohort 2 (200 mg BID)Preliminary Activity and Safety Summary[] 16 patients enrolled[] 9 patients have reached 8 weeks of KD025 (first clinical assessment) [] 6 of°the 9 patients have achieved a response at 8 weeks [] No drug-related SAEsData as of July 11, 201716

  17. Slide 17: KD025 in cGVHD: Regulatory Strategy

    KD025 in cGVHD: Regulatory StrategyData Readout Plan[] Submit additional data from all cohorts for presentation at scientific°conferencesRegulatory Strategy[] Dialogue with FDA expected in 2H 2017 to obtain guidance on regulatory path°for approval [] Path for approval in steroid dependent or refract

  18. Slide 18: KD025 in Fibrotic Disease: Idiopathic Pulmonary Fibrosis (IPF)

    KD025 in Fibrotic Disease: Idiopathic Pulmonary Fibrosis (IPF)IPF: Major Unmet Medical NeedIPF is a progressive fibrotic disease of the lungs-- Believed to be caused by repetitive environmental injury to lining of the°lungs and resulting abnormal wound-healing responses-- Prolonged activation of wou

  19. Slide 19: KD025 Attenuates Pulmonary Fibrosis in Bleomycin Model

    KD025 Attenuates Pulmonary Fibrosis in Bleomycin Model»Intratracheal Bleomycin »KD025 treatment administered when fibrosis is already established Tissue Harvest (orally, 50, 100 or 150 mg QD)»Day:0 ¨821»Normal Lung Pre-Treatment Lung IntratrachealVehicle or KD025Bleomycin Day 0Day 8Treatment: Day 21

  20. Slide 20: KD025 in IPF: Ongoing Clinical Study

    KD025 in IPF: Ongoing Clinical StudyRandomized, Open-label Phase 2 Study of KD025 in IPF[] 24-week study enrolling 36 patients who have received or been offered°pirfenidone and/or nintedanib [] Two cohorts:-- KD025 400 mg QD (24 patients) -- Best supportive care (12 patients)[] Primary endpoint: Saf

  21. Slide 21: KD025: Ongoing Phase 2 Study in Psoriasis

    KD025: Ongoing Phase 2 Study in Psoriasis¨¨¨¨¨Randomized, Double-blind, Placebo-controlled Study of KD025 in Moderate to°Severe Psoriasis [] 16-week study enrolling 180 patients across five cohorts:-- KD025 200 mg QD -- KD025 200 mg BID -- KD025 400 mg QD-- KD025 600 mg QD (400 mg a.m., 200 mg p.m.)

  22. Slide 22: KD025: Demonstrated Clinical Activity in Ph2 Psoriasis Studies

    KD025: Demonstrated Clinical Activity in Ph2 Psoriasis Studies Completed Phase 2 Clinical Studies of°KD025 in Psoriasis [] Kadmon has completed two Phase 2 pilot studies of KD025°in psoriasis:-- Phase 2a: KD025 200 mg QD for 4 weeks-- Phase 2: Multiple KD025 doses/cohorts (400 mg -- 800 mg) for 12 w

  23. Slide 23: Preclinical Programs

    Preclinical Programs

  24. Slide 24: Kadmon: Preclinical Pipeline

    Kadmon: Preclinical PipelineRobust Preclinical Discovery Platform[] 30-person team in research, preclinical development and CMC, working on°small molecules and proteins [] Lead research product candidate in development°from biologics, KD033, an anti-PD-L1/IL-15 fusion protein24

  25. Slide 25: Company Summary

    Company Summary»[] KD025: Selective ROCK2 inhibitor in three ongoing Phase 2 clinical trials:»¨¨¨-- Open-label, dose-finding trial in chronic graft-versus-host disease (cGVHD)»¨¨¨¨¨¨¨[] Initial results announced July 2017¨¨Leader in R&D of »¨¨¨-- Randomized, open-label trial in idiopathic pulmonary

  26. Slide 26: Financial Profile

    Financial Profile KDMN°Financial Summary [] Kadmon completed its IPO on August 1, 2016[] Completed private placement on March 13, 2017; gross proceeds of approx. []°51,846,521 common shares outstanding as of August 3, 2017 [] Cash and cash°equivalents of $26.2mm as of June 30, 2017 [] Trades on the

Kadmon Holdings — Investor Presentation (September 2017) on 6ix